Contrave(®) is a combination of naltrexone hydrochloride extended release and 
bupropion hydrochloride extended release for the treatment of obesity, and is 
used with lifestyle modification. Its safety and efficacy were assessed in four 
randomized, double-blind, placebo-controlled, 56-week Phase III clinical trials 
in 4536 adult subjects: COR-1, COR-II, COR-BMOD and COR-DM. All four studies 
demonstrated statistically significant and clinically meaningful weight loss 
following up to 52 weeks of treatment with naltrexone/bupropion compared with 
placebo. The average weight loss from baseline across the four studies was 
approximately 11-22 lbs (5-9 kg). Results show the efficacy of Contrave for 
weight loss, as well as significant improvements in cardiometabolic markers. 
This review focuses on the four studies, their outcomes and the mechanism of 
action of Contrave.